



**Maidstone and
Tunbridge Wells**
NHS Trust

Ref: FOI/GS/ID 7287

Please reply to:
FOI Administrator
Trust Management
Maidstone Hospital
Hermitage Lane
Maidstone, Kent
ME16 9QQ
Email: mtw-tr.foiadmin@nhs.net
www.mtw.nhs.uk

11 March 2022

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Triple-Negative (ER negative, PR negative and HER2 negative) breast cancer.

You asked:

Could you please tell me how many patients you have treated for Triple Negative breast cancer in the last 3 months with the following systemic anti-cancer therapies:

- a) Anthracycline (e.g. doxorubicin) as single agent*
- b) Atezolizumab + nab-paclitaxel or paclitaxel*
- c) Capecitabine as a single agent*
- d) Eribulin as a single agent or in combination*
- e) PARP inhibitor (e.g. Olaparib)*
- f) Pembrolizumab + chemotherapy*
- g) Platinum (e.g. carboplatin, cisplatin) as a single agent*
- h) Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent*
- i) Taxane + Anthracycline based combinations*
- j) Vinorelbine as a single agent*
- k) Other active systemic anti-cancer therapy*

Trust response:

- a) 0
- b) 0
- c) 1
- d) 0
- e) 0
- f) 0
- g) 0
- h) 1

- i) 0
- j) 0
- k) 21

The period looked at is 1/12/2021-28/2/2022.